Specifically, our data suggests that inhibitors against intracellular VEGFR-1 may be more effective than those inhibiting extracellular VEGFR-1 because VEGFR-1 is expressed in the cytoplasm of tumor cells but not on the membrane. Here, FLT1 is linked to neoplasm.